The management of early prostate cancer: A review

East African Medical Journal

Volumn 84, Issue 9 SUPPL., 2007, Pages

  Ngugi, P M ^a,b   Magoha, G A O ^a  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AFRICA; BLOOD; DIGITAL RECTAL EXAMINATION; HUMAN; MALE; MASS SCREENING; METHODOLOGY; PROSTATE TUMOR; PROSTATECTOMY; REVIEW; TREATMENT OUTCOME;

AFRICA; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 36348993642     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Spanjol J., Maricic A., Cicvaric T., et al. Epidemiology of prostate cancer inthe mediterranean population of Croatia-a thirty-three year retrospective study. Coll. Antropol. 2007; 31: 235-239.
2. Green R.T., Murray T., Bolden S. et al Cancer Statistics 2000. CA Cancer J. Clin. 2000; 50:7-33.
3. Lepor H. Management of clinically localized prostate cancer. Urol. 2004; 6(Suppl 2): 53-512.
4. Magoha G.A. Screening and early detection for prostate cancer. East Afr. Med. J. 1997; 74: 664-667.
5. Moul J.W. Treatment options for prostate cancer. Part I stage grade, PSA and changes in the 1990's. Am. J. Managed Care. 1998; 4: 1031-1036.
6. Stone N.N., De Antoni F.P. and Crawford E.D. Screening for prostate cancer by digital rectal examination and prostate specific antigen. Results of prostate cancer awareness week. 1989-1992. Urology. 1994; 44:18-25.
7. Gonzalgo M.L. and Carter H. B. Update on PSA testing. J. Natl. Compr. Cane. Netw. 2007; 5:737-742.
8. st time ever in 1990's. J. Natl. 1996.
9. Bartch G., Horninger W., and Klocker H., et al. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the Federal state of Tyrol, Austria. J. Urol. 2000; 163: 88. Abstract 387.
10. Bill-Axelson A., Holmbergl and Ruutu M. et al. Radical prostatectomy vs watchful waiting in early prostate cancer. N. Eng. J. Med. 2005; 352: 1977-1984.
11. Nelen V. Epidemiology of prostate cancer. Recent Results. Cancer Res. 2007; 175:1-8.
12. Catalona W. J., Smith D. S. and Ratliff T. L., et al. Measurement of serum PSA as a screening test for prostate cancer. N. Engl. J. Med. 1991; 324: 1156-1161.
13. Brewer M. K., Chetner M. P. and Beatie J., et al Screening for prostatic carcinoma with PSA. J. Urol. 1992;147: 841-845.
14. Brewer M. K. Prostate specific antigen. In Lepor H; Editor. Prostatic diseases. Philadelphia; W. B. Saunders Company 2000. PP 381-390.
15. Catalona W. J., Partin A. W. and Chan D. W. et al Prostate cancer detection in men with PSA concentrates of 2.8 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with PSA measurements. JAMA. 1998; 277: 1452.
16. Yawe K. T., Tahir M. B and Nggada H. A. Prostate cancer in Maiduguri. West Afr. J. Med. 2006; 25: 298-300.
17. Heyns C.F., Mathee S., Isaacs A. et al. Problems with prostate specific antigen screening for prostate cancer in the primary healthcare setting in South Africa. BJU Int. 2003; 91: 785-788.
18. Khouaja K., Ben Sorba N., Bouslama A., Youssef A. and Taher Mosbah A. An experience of individual and early diagnosis of prostate cancer in a Tunisian centre. Prog. Urol. 2005; 15: 255-259.
19. Quinlan M.R., Teahan S., Mulvin D. and Quinlan D.M. Is digital rectal examination still necessary in the early detection of prostate cancer? Ir. J. Med Sci. 2007;176:161-163.
20. Vis A.N., Roemeling S., Reedijk A.M., et al. Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohort. Eur Urol. 2007; Epub. June 12.
21. Makarov D.V. and Partin A. W. Prostate-Cancer risk stratification via early PSA testing. Rev Urol. 2007; 9:91-92.
22. Vickers A.J., Ulmert D., Serio A. M. et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy. Int. J. Cancer. 2007; Epub, July 26 2007.
23. Rai T., Clements A., Bukach C., et al. What influences men's decision to have a prostate-specific antigen test? A qualitative study. Fam Pract. 2007; 24:365-371.
24. Hodge K. K., McNeal J. E., Terris M. K., et al Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J. Urol. 1989; 142: 71-75.
25. Levine M. A., Itmann M., Mecamed J.; et al. Two consecutive sets of transrectal ultrasound guided core biopsies of the prostate. J. Urol. 1998; 159: 471-475.
26. Esken L. A., Bare R. L. and McCullough D. I. Systematic 15 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J. Urol. 1997;157: 199-202.
27. Tenke P., Horti J., Balint P. and Kovacs B. Prostate cancer screening. Recent results. Cancer Res. 2007;175: 65-81.
28. Han M., Patin A. W. and Pound C. R. et al. Long term biochemical disease free and cancer specific survival following anatomic radical prostatectomy. The 15 years John Hopkins experience. Urol. Clin. North Am. 2001; 28: 555-565.
29. Lepor H. Selecting candidates for radical prostatectomy. In: Lepor H. Editor. Prostatic diseases. Philadelphia, W. B. Saunders Company 2000, pp 478-487.
30. Per-Anders Abrahamsson Active surveillance Vs radical prostatectomy. BJU Intern. 2007: 100(Suppl. 2): 26-28.
31. Paulson D. F. Randomized series of treatment with surgery Vs radiation for prostate adenocarcinoma. Presented at:NCI consensus developent conference on management of clinically localized cancer, June 1987.
32. Presti J. C. JR. Prostate biopsy strategies. Nat Clin Pract. Urol. 2007; 4:505-511. P MID: 17823604.
33. Pinthus J. H., Pacik D. and Ramon J. Diagnosis of prostate cancer. Recent results Cancer Res. 2007;175:83-99.
34. Martis G., Diana M., Ombres M., et al. Retropubic versus perineal radical prostatectomy in early prostate cancer: eight-year experience. J. Surg. Oncol. 2007; 95:513-518.
35. Raman J. D., Dong S., Levinson A., et al. Robotic radical prostatectomy: operative technique, outcomes, and learning curve. J. Soc. Laparoendoscopic Surg. 2007; 11:1-7.
36. Venkitaraman R., Norman A., Woode-Amissah R., et al. Predictors of histological disease progression in untreated, localized prostate cancer. J. Urol. 2007; 178:833-837.
37. Wirth M.P., Hakenberg O.W. And Froehner M. Optimal treatment of locally advanced prostate cancer. World J. Urol. 2007; 25:169-176.
38. Pucar D., Hricak H., Shukla-Dave A. et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int. J. Radiat. Oncol. Biol.Phys. 2007; 69:62-69.
39. Wirth M., Tyrrell C., Wallace M. et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology. 2001; 58:146-151.
40. Rouvière O., Souchon R., Salomir R., et al. High-intensity focused ultrasound ablation of prostate cancer: Effective treatment requiring accurate imaging. Eur. J. Radiol. 2007; 63:317-327.
41. Daubenmier J. J., Weidner G., Marlin R., et al. Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology. 2006; 67:125-130.
42. Hardie C., Parker C., Norman A., et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int. 2005; 95:956-960.
43. Venkitaraman R., Norman A., Woode-Amissah R., et al. Predictors of histological disease progression in untreated, localized prostate cancer. J. Urol. 2007; 178: 833-837.
44. Lepor H., Nieder A. M. and Ferrandino M. N. Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases. J. Urol. 2001; 166:1729-1733.
45. Lerner S. E., Blute M. L., Lieber M. M. et al Morbidity of contemporary radical retropublic prostatectomy for localized prostate cancer. Oncology. 1995; 9:379-382.
46. Eastham J. A., Kattan M., Rogers E. et al Risk factors for urinary incontinence after radical prostatectomy. J. Urol. 1996; 156: 1707-1713.
47. Pensod D. F. The effect of erectile dysfunction on quality of life following treatment of localised prostate cancer. Rev. Urol. 2001; 3: 113-119.
48. Sanford J. L., Feng Z. et al. Urinary and sexual function after radical prostatectomy for clinically localised prostate cancer: the prostate cancer outcomes study. JAMA. 2000; 283: 354.
49. Michalski J. M., Purdy J. A., Winter K. et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3 DOG/RTOG 9406. Int. J. Radiant Oncol. Biol. Phys. 2000; 46: 391-402.
50. Talcott J. L., Clark J. A., Stark P. C. et al. Long term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J. Urol. 2001; 166: 494-499.